Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + AE37 peptide vaccine
- Development stage
- Unknown
- Lead developer
- Generex Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
Pembrolizumab + AE37 peptide vaccine is an investigational combination therapy for metastatic triple-negative breast cancer (TNBC). Pembrolizumab is a monoclonal antibody immune checkpoint inhibitor that blocks PD-1, leading to the activation of T-cell-mediated immune responses against tumors. AE37 is a therapeutic peptide vaccine derived from the HER2 protein combined with the Ii-Key motif, designed to activate CD4+ T-helper cells and enhance immune recognition of tumor cells expressing HER2. The rationale for the combination is that AE37 may prime the immune system to increase responsiveness to pembrolizumab by expanding the population of immune-activated tumors. This combination is currently under investigation in phase II clinical trials for TNBC, aiming to leverage complementary mechanisms to improve outcomes in patients not responsive to monotherapy[1][3][5][9].
- Brand names
- Keytruda
- Other names
- pembrolizumab + AE37
02
Targets
MHC II (Major histocompatibility complex class II receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + AE37 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + AE37 peptide vaccine.